reports
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® ...
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the presentation of four posters highlighting positive new data on MIPLYFFA® (arimoclomol...
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday,...
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's tr...
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22...
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and therapeutic advances in Niemann-Pick disease type C (NPC) CELEBRATION, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today...
Barnes & Noble Education Reports First Half Fiscal 2026 Results and Fi...
Barnes & Noble Education Reports First Half Fiscal 2026 Results and Files Related Quarterly Reports BNC First Day Program Revenue Increases 29.0% in 26 weeks ended November 1, 2025 Net Income Improves to $6.7 million Company Reports Total Net Debt of $110.8 million as of November 1, 2025, a $55.1 million Decline Year-Over-Year Reiterates Prior Fiscal 2026 Outlook, including $65-$75 million in Adjusted EBITDA FLORHAM PARK, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE: BNED), (“Barnes & Noble Education,” “BNED,” “the Company,” “we,” “us,” “our”), a leadi...
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcar...
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference a...
Barnes & Noble College Announces New Partnership with the University o...
Barnes & Noble College Announces New Partnership with the University of California, Berkeley to Modernize Retail Operations and Support the Campus’s Highest Priority Goals FLORHAM PARK, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble College (BNC), a Barnes & Noble Education, Inc. (NYSE: BNED) company and leading solutions provider for higher education, today announced a new partnership with the University of California, Berkeley, one of the nation’s top public universities. Under the agreement, beginning January 20, 2026, Barnes & Noble College will manage all retail, course mater...
Zevra Therapeutics Executes Distribution Agreement to Broaden Access t...
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar, an Ireland-based pharmaceutical services provider with a proven record of success in global warehousing, distribution and supply ch...
Barnes & Noble Education Files “Super 10-K”, Reporting Full-Year Fisca...
Barnes & Noble Education Files “Super 10-K”, Reporting Full-Year Fiscal 2025 Financial Results, and Restated Financial Results for Prior Periods Fiscal 2025 Results Consistent with Preliminary Unaudited Ranges Disclosed November 25, 2025 BNC First Day Program Revenue Increases 25% in 2025; Fall 2025 First Day Complete Enrollment Grows 24% Company Reports Total Net Debt of $94 million at End of Fiscal 2025, a $92 million Decrease Year-Over-Year Reiterates Prior Fiscal 2026 Outlook FLORHAM PARK, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE: BNED), (“Barne...
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company’s common stock (the “Inducement Awards”) to three new employees pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”)....
Paycom Software Inc: 1 director
A director at Paycom Software Inc sold 2,192 shares at 165.849USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; ...
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company’s Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today. "We are pleased to welcome Alicia to our Board at this important juncture, as her expe...
Barnes & Noble Education Announces Preliminary Full-Year Fiscal 2025 a...
Barnes & Noble Education Announces Preliminary Full-Year Fiscal 2025 and Year-to-Date Fiscal 2026 Unaudited Financial Results Company Announces the Conclusion and Findings of Internal Investigation Releases Preliminary FY2025 and First Half 2026 Results First Day Complete Enrollment for Fall 2025 Estimated to Grow 24%* Board of Directors Pleased with Revenue Growth & Strong Improvements in Operating Results and Balance Sheet FLORHAM PARK, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE: BNED), (“Barnes & Noble Education,” “BNED,” “the Company,” “we...
Zevra Therapeutics, Inc. Announces CFO Transition
Zevra Therapeutics, Inc. Announces CFO Transition CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities. "Since joining the Company in 2015, LaDuane has provided steady leadership and invaluable guidance, leavin...
Zevra Reports Third Quarter 2025 Financial Results and Corporate Updat...
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update 2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-posi...
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovat...
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one mee...
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Cal...
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call - Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 CELEBRATION, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the third quarter 2025 on Wednesday, November 5, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m....
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
GWRS INC.
AROC GLOBAL WATER RESOURCES
ZIVO ARCHROCK INC.
CPSH ZIVO BIOSCIENCE
FUND INC.
ARVN CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
BCDA INC.
SAVA ARVINAS HOLDING
DX FIRST GUARANTY BANCSHARES
AOUT BIOCARDIA
ACET CASSAVA SCIENCES
ALTM DYNEX CAPITAL INC.
CGEM AMERICAN OUTDOOR BRANDS
OPEN INC.
GGZ ADICET BIO INC
IMRX ALTUS MIDSTREAM COMPANY (A)
ABSI CULLINAN ONCOLOGY INC
PEPG OPENDOOR TECHNOLOGIES INC.
MRVL GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
UAMY IMMUNEERING CORP
PRAX ABSCI CORP
LAW PEPGEN INC
MRAI MARVEL BIOSCIENCES CORP
JSPR U S ANTIMONY CORP
BDSX PRAXIS PRECISION MEDICINES INC
SABS CS DISCO INC
MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
PSEC PROSPECT CAPITAL CORPORATION
NVCR NOVOCURE LTD.
MTDR MATADOR RESOURCES COMPANY
FCN FTI CONSULTING INC.
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
CULP CULP INC.
PBHC PATHFINDER BANCORP INC.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BSM BLACK STONE MINERALS LP
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
CELC SMARTSPACE SOFTWARE
MBIN CELCUITY
CCEL MERCHANTS BANCORP
BCDA CRYO-CELL INTERNATIONAL
DX BIOCARDIA
COO DYNEX CAPITAL INC.
AOUT THE COOPER COMPANIES INC.
ALXO AMERICAN OUTDOOR BRANDS
SMMT INC.
NAUT ALX ONCOLOGY HOLDINGS
ENOV SUMMIT THERAPEUTICS INC
MRVL NAUTILUS BIOTECHNOLOGY INC
UAMY ENOVIS CORPORATION
NCDL MARVEL BIOSCIENCES CORP
NEXT U S ANTIMONY CORP
SFD NUVEEN CHURCHILL DIRECT LENDING CORP
AFCG NEXTSOURCE MATERIALS INC.
SI SMITHFIELD FOODS INC.
JSPR AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
AMPLITUDE HEALTHCARE ACQUISITION CORP
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company’s common stock (the “Inducement Awards”) to two new employees pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). E...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
MBIN SMARTSPACE SOFTWARE
AROC MERCHANTS BANCORP
FUND ARCHROCK INC.
ARVN ROYCE FOCUS TRUST
FGBI INC.
BCDA ARVINAS HOLDING
UUU FIRST GUARANTY BANCSHARES
SAVA BIOCARDIA
DX UNIVERSAL SECURITY INSTRUMENTS INC.
AOUT CASSAVA SCIENCES
ALXO DYNEX CAPITAL INC.
ALTM AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
GGZ ALTUS MIDSTREAM COMPANY (A)
IMRX ALPHA METALLURGICAL RESOURCES INC
ABSI OPENDOOR TECHNOLOGIES INC.
RYAN GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
MRVL ABSCI CORP
BUKS RYAN SPECIALTY GROUP HLDGS INC
OBLG PEPGEN INC
VANI MARVEL BIOSCIENCES CORP
UAMY BUTLER NATIONAL CORP
PRAX OBLONG INC
NCDL VIVANI MEDICAL INC
NEXT U S ANTIMONY CORP
MRAI PRAXIS PRECISION MEDICINES INC
JSPR NUVEEN CHURCHILL DIRECT LENDING CORP
BDSX NEXTSOURCE MATERIALS INC.
SABS MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.